Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 4/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15066708 | 1.00 | MAOB (0.49) | MAOBBACE1SLC16A3MAPTALDH1A1 | |
| SCHEMBL15086460 | 1.00 | MAOB (0.49) | MAOBBACE1SLC16A3MAPTALDH1A1 | |
| SCHEMBL15065831 | 0.87 | SLC16A3 (0.64) | MAOBBACE1SLC16A3MAPTALDH1A1 | |
| SCHEMBL15066762 | 0.87 | MAOB (0.53) | MAOBBACE1SLC16A3MAPTALDH1A1 | |
| SCHEMBL15065820 | 0.85 | SLC16A3 (0.57) | SLC16A3MAPTALDH1A1LMNAKDM4E | |
| SCHEMBL16669729 | 0.85 | SLC16A3 (0.57) | SLC16A3MAPTALDH1A1LMNAKDM4E | |
| SCHEMBL15066724 | 0.84 | MAOB (0.53) | MAOBBACE1SLC16A3MAPTALDH1A1 | |
| SCHEMBL15086510 | 0.83 | MAOB (0.49) | MAOBBACE1SLC16A3MAPTALDH1A1 | |
| SCHEMBL15066750 | 0.83 | MAOB (0.49) | MAOBBACE1SLC16A3MAPTALDH1A1 | |
| SCHEMBL15065672 | 0.82 | BACE1 (0.51) | MAOBBACE1SLC16A3MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797592-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM17, RBM22 | MAOB 1733/4885BACE1 1158/4885SLC16A3 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.